Literature DB >> 8097057

The CD26 antigen is coupled to protein tyrosine phosphorylation and implicated in CD16-mediated lysis in natural killer cells.

J A Madueño1, E Muñoz, V Blazquez, R Gonzalez, P Aparicio, J Peña.   

Abstract

The levels of CD26 expression, their capacity to induce protein tyrosine phosphorylation and their functional implication in natural killer (NK) cytolysis have been studied. It was found that only a small fraction (12-15%) of peripheral NK cells expresses CD26 compared with the high expression (99%) found in NK clones. The protein tyrosine phosphorylation mediated by means of CD26 activation was studied in NK cells treated with the anti-CD26 MoAb 134-2C2, and two new proteins of 50 and 21 kDa appeared phosphorylated in tyrosine residues. To study the influence of CD26 antigen in NK lysis, we analysed the lytic capacity of NK cells stimulated with different anti-CD26 MoAbs or after separation into CD26+ and CD26- subsets and using K562 as target cells. Under these conditions, no differences were found in the chromium release by the target cells. Redirected lysis through CD16 was also measured by arming the effector cells (CD26+ and CD26-) with anti-CD16 antibody and using K562 as target cells. It was found that CD26- cells showed significantly less CD16-dependent lysis than CD26+ cells. These results indicate that CD26 is related to the CD16-dependent lysis but not to NK cytolysis which may be caused by mediation of protein tyrosine phosphorylation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097057     DOI: 10.1111/j.1365-3083.1993.tb03313.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

1.  Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase.

Authors:  M Hegen; J Kameoka; R P Dong; S F Schlossman; C Morimoto
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

Review 2.  Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.

Authors:  C Klemann; L Wagner; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-05-13       Impact factor: 4.330

3.  Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.

Authors:  Susann Szmania; Natalia Lapteva; Tarun Garg; Amy Greenway; Joshuah Lingo; Bijay Nair; Katie Stone; Emily Woods; Junaid Khan; Justin Stivers; Susan Panozzo; Dario Campana; William T Bellamy; Molly Robbins; Joshua Epstein; Shmuel Yaccoby; Sarah Waheed; Adrian Gee; Michele Cottler-Fox; Cliona Rooney; Bart Barlogie; Frits van Rhee
Journal:  J Immunother       Date:  2015-01       Impact factor: 4.456

Review 4.  Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease.

Authors:  Jie Huang; Xinxin Liu; Yingying Wei; Xinlu Li; Shupei Gao; Lingli Dong; Xiaoquan Rao; Jixin Zhong
Journal:  Front Immunol       Date:  2022-03-04       Impact factor: 7.561

5.  Altered expressions of CXCR4 and CD26 on T-helper lymphocytes in hereditary hemorrhagic telangiectasia.

Authors:  Alexandre Guilhem; Pierre Portalès; Sophie Dupuis-Girod; Sophie Rivière; Thierry Vincent
Journal:  Orphanet J Rare Dis       Date:  2021-12-14       Impact factor: 4.123

6.  Genome wide transcriptional analysis of resting and IL2 activated human natural killer cells: gene expression signatures indicative of novel molecular signaling pathways.

Authors:  Karen Dybkaer; Javeed Iqbal; Guimei Zhou; Huimin Geng; Li Xiao; Alexander Schmitz; Francesco d'Amore; Wing C Chan
Journal:  BMC Genomics       Date:  2007-07-10       Impact factor: 3.969

Review 7.  The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis.

Authors:  Yannick Waumans; Lesley Baerts; Kaat Kehoe; Anne-Marie Lambeir; Ingrid De Meester
Journal:  Front Immunol       Date:  2015-08-07       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.